DDrare: Database of Drug Development for Rare Diseases

Vx15/2503 (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	1
13	Multiple sclerosis/Neuromyelitis optica	1

8. Huntington disease [ 197 clinical trials, 171 drugs, (DrugBank: 54 drugs), 82 drug target genes, 144 drug target pathways]

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 197 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02481674 (ClinicalTrials.gov)	July 2015	19/6/2015	A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503)	A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503	Huntington's Disease	Drug: VX15/2503;Drug: Placebo	Vaccinex Inc.	Huntington Study Group	Completed	21 Years	N/A	All	301	Phase 2	United States;Canada

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01764737 (ClinicalTrials.gov)	December 2012	3/1/2013	Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: VX15/2503;Drug: Placebo	Vaccinex Inc.	PRA Health Sciences	Completed	18 Years	60 Years	Both	50	Phase 1	United States